{"id":"https://openalex.org/W2943618149","doi":"https://doi.org/10.1212/wnl.92.15_supplement.s4.003","title":"Once-Daily Opicapone Increases ON-Time in Patients with Parkinson\u2019s Disease: Results from Two Phase 3 Studies (S4.003)","display_name":"Once-Daily Opicapone Increases ON-Time in Patients with Parkinson\u2019s Disease: Results from Two Phase 3 Studies (S4.003)","publication_year":2019,"publication_date":"2019-04-09","ids":{"openalex":"https://openalex.org/W2943618149","doi":"https://doi.org/10.1212/wnl.92.15_supplement.s4.003","mag":"2943618149"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.92.15_supplement.s4.003","doi":"https://doi.org/10.1212/wnl.92.15_supplement.s4.003","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.92.15_supplement.s4.003","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017122855","display_name":"Peter A. LeWitt","orcid":"https://orcid.org/0000-0002-4976-4445","observed_orcids":["https://orcid.org/0000-0002-4976-4445"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]},{"id":"https://openalex.org/I2803043754","display_name":"Henry Ford Hospital","ror":"https://ror.org/0193sb042","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I154057602","https://openalex.org/I2803043754"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter LeWitt","raw_affiliation_strings":["Henry Ford Hospital and Department of Neurology, Wayne State University School of Medicine West Bloomfield MI United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Henry Ford Hospital and Department of Neurology, Wayne State University School of Medicine West Bloomfield MI United States","institution_ids":["https://openalex.org/I185443292","https://openalex.org/I2803043754"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064135529","display_name":"Daniel O. Claassen","orcid":"https://orcid.org/0000-0002-9853-4902","observed_orcids":["https://orcid.org/0000-0002-9853-4902"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Claassen","raw_affiliation_strings":["Vanderbilt University Medical Center Nashville TN United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center Nashville TN United States","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kurt Olson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kurt Olson","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113065584","display_name":"Khodayar Farahmand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khodayar Farahmand","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076964650","display_name":"Scott W. K. Siegert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Siegert","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003154757","display_name":"Mena Alrais","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mena Alrais","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071860003","display_name":"Jos\u00e9\u2010Francisco Rocha","orcid":"https://orcid.org/0000-0003-2611-4850","observed_orcids":["https://orcid.org/0000-0003-2611-4850"]},"institutions":[{"id":"https://openalex.org/I108511484","display_name":"Bial (Portugal)","ror":"https://ror.org/02htdjb57","country_code":"PT","type":"company","lineage":["https://openalex.org/I108511484"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Jos\u00e9-Francisco Rocha","raw_affiliation_strings":["BIAL-Portela & Ca SA Sao Mamede do Coronado Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BIAL-Portela & Ca SA Sao Mamede do Coronado Portugal","institution_ids":["https://openalex.org/I108511484"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078712323","display_name":"Patr\u0131\u0301cio Soares-da-Silva","orcid":"https://orcid.org/0000-0002-2446-5078","observed_orcids":["https://orcid.org/0000-0002-2446-5078"]},"institutions":[{"id":"https://openalex.org/I182534213","display_name":"Universidade do Porto","ror":"https://ror.org/043pwc612","country_code":"PT","type":"education","lineage":["https://openalex.org/I182534213"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Patr\u00edcio Soares-da-Silva","raw_affiliation_strings":["BIAL-Portela & Ca SA and University Porto Porto Portugal"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BIAL-Portela & Ca SA and University Porto Porto Portugal","institution_ids":["https://openalex.org/I182534213"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036151807","display_name":"Grace S. Lin Liang","orcid":"https://orcid.org/0009-0008-2581-4891","observed_orcids":["https://orcid.org/0009-0008-2581-4891"]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grace Liang","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.05135177,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"92","issue":"15_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10114","display_name":"Balance, Gait, and Falls Prevention","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3612","display_name":"Physical Therapy, Sports Therapy and Rehabilitation"},"field":{"id":"https://openalex.org/fields/36","display_name":"Health Professions"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/opicapone","display_name":"opicapone","score":0.9879999756813049},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9819999933242798},{"id":"https://openalex.org/keywords/on-time","display_name":"on time","score":0.8159999847412109},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.8619999885559082},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.48500001430511475}],"concepts":[{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.6225922107696533},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6162810921669006},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.43521246314048767},{"id":"https://openalex.org/C74909509","wikidata":"https://www.wikidata.org/wiki/Q10387","display_name":"Gerontology","level":1,"score":0.35180479288101196},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.3480288088321686},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2731260657310486}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.92.15_supplement.s4.003","doi":"https://doi.org/10.1212/wnl.92.15_supplement.s4.003","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.92.15_supplement.s4.003","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389447227","https://openalex.org/W2915011801","https://openalex.org/W7164131295","https://openalex.org/W4212768725","https://openalex.org/W3115426834","https://openalex.org/W2990876746","https://openalex.org/W2341821917","https://openalex.org/W3108148252","https://openalex.org/W3138988857","https://openalex.org/W4389447939"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"evaluate":[2],"changes":[3,112,217],"with":[4,46,72,138,215,294,316,390,435,457,484,506,535,564],"once-daily":[5],"opicapone":[6,52,73,133,173,285],"in":[7,9,36,56,99,115,164,204,211,226,255,291],"ON-time":[8,117,166,205,287],"Parkinson\u2019s":[10,363],"disease":[11],"(PD).":[12],"Background:":[13],"Catechol-O-methyltransferase":[14],"(COMT)":[15],"inhibitors":[16],"were":[17,95,209],"developed":[18],"to":[19,42,89,97,161,221,270,544],"prolong":[20],"the":[21,37,100,131,243,461,512],"clinical":[22],"actions":[23],"of":[24,51,105,230,251,257,411,463,508,514],"levodopa.":[25,90],"Opicapone":[26],"is":[27],"a":[28,141,156,249,308,382,427,449,476,498,527,556],"novel,":[29],"highly-selective,":[30],"peripheral":[31],"COMT":[32],"inhibitor":[33],"under":[34],"development":[35],"U.S.":[38],"as":[39,122,140],"an":[40],"adjunct":[41],"levodopa":[43],"for":[44,85,130,172,233,239,262,304,362,378,423,445,472,494,523,552],"PD":[45,292],"motor":[47,295],"fluctuations.":[48,296],"The":[49],"efficacy":[50],"has":[53,300,345,374,398,419,441,468,490,519,542,548],"been":[54],"evaluated":[55],"two":[57],"international":[58],"Phase":[59],"3":[60],"studies":[61],"(BIPARK-1":[62,81],"[NCT01568073],":[63],"BIPARK-2":[64,193,240],"[NCT01227655]).":[65],"Design/Methods:":[66],"Participants":[67,91],"received":[68,301,346,375,399,420,442,469,491,520,549],"double-blind":[69],"(DB)":[70],"treatment":[71,94],"(5mg":[74],"[BIPARK-1":[75],"only],":[76],"25mg,":[77],"50mg),":[78],"entacapone":[79],"200mg":[80],"only),":[82],"or":[83,126,276,313,387,432,454,481,503,532,561],"placebo":[84,176],"14\u201315":[86],"weeks":[87],"added":[88],"completing":[92],"DB":[93,219,245],"eligible":[96],"enroll":[98],"1-year":[101],"open-label":[102],"(OL)":[103],"phase":[104],"each":[106],"study.":[107,465,516],"Efficacy":[108],"analyses":[109],"included":[110],"mean":[111,178,216],"from":[113,159,192,218,349,402],"baseline":[114,160,220],"absolute":[116,165],"without":[118,167,206,288],"troublesome":[119,168,207,289],"dyskinesia":[120,125,139,169,208,252,267,278,290],"(defined":[121],"either":[123],"no":[124],"non-troublesome":[127],"dyskinesia).":[128],"Results":[129],"50mg":[132,174],"dose":[134],"are":[135],"presented,":[136],"along":[137],"treatment-emergent":[142],"adverse":[143],"event":[144],"(TEAE).":[145],"Results:":[146],"In":[147,242],"BIPARK-1":[148,234],"(opicapone":[149],"at":[150],"5mg=119,":[151],"25mg=116,":[152],"50mg=115;":[153],"entacapone=120;":[154],"placebo=120),":[155],"significant":[157],"increase":[158],"Week":[162],"14/15":[163],"was":[170,253],"found":[171],"versus":[175],"(least-squares":[177],"change":[179],"[\u00b1standard":[180],"error],":[181],"hours):":[182],"50mg,":[183,197],"1.9\u00b10.2;":[184],"placebo,":[185,199,274,281],"0.9\u00b10.2;":[186],"P":[187,201],"=0.002.":[188],"Similar":[189],"results":[190],"arose":[191],"(25mg=125,":[194],"50mg=147,":[195],"placebo=135):":[196],"1.7\u00b10.3;":[198],"0.9\u00b10.3;":[200],"=0.025.":[202],"Improvements":[203],"sustained":[210],"long-term":[212],"extension":[213],"studies,":[214],"OL":[222],"endpoint":[223],"(\u00b1standard":[224],"deviation)":[225],"all":[227,258],"opicapone-treated":[228,259],"participants":[229],"2.0\u00b12.6":[231],"hours":[232,238],"(N=494)":[235],"and":[236,340,369],"1.8\u00b13.2":[237],"(N=339).":[241],"pooled":[244],"safety":[246],"population":[247],"(N=631),":[248],"TEAE":[250,268],"reported":[254],"17.4%":[256],"(versus":[260],"6.2%":[261],"placebo).":[263],"Few":[264],"subjects":[265],"had":[266],"leading":[269],"discontinuation":[271],"(opicapone,":[272,279],"1.9%;":[273],"0.4%)":[275],"serious":[277],"0.3%,":[280],"0%).":[282],"Conclusions:":[283],"Once-daily":[284],"increased":[286],"patients":[293],"Disclosure:":[297],"Dr.":[298,343,372,396,417,439,466,488,517,540,546],"LeWitt":[299,344],"personal":[302,376,421,443,470,492,521,550],"compensation":[303,377,422,444,471,493,522,551],"consulting,":[305,379,424,446,473,495,524,553],"serving":[306,380,425,447,474,496,525,554],"on":[307,381,426,448,475,497,526,555],"scientific":[309,383,428,450,477,499,528,557],"advisory":[310,384,429,451,478,500,529,558],"board,":[311,385,430,452,479,501,530,559],"speaking,":[312,386,431,453,480,502,531,560],"other":[314,388,433,455,482,504,533,562],"activities":[315,389,434,456,483,505,534,563],"Acorda":[317],"Therapeutics,":[318,335],"Adamas":[319],"Pharmaceuticals,":[320,325,328,338],"Britannia,":[321],"Intec":[322,355],"Pharma,":[323,356],"Jazz":[324],"Lundbeck,":[326,357,393],"Acadia":[327],"Merz,":[329],"NeuroDerm":[330],"Ltd,":[331],"Pfizer,":[332],"Prexton,":[333],"Sage":[334],"Scion,":[336],"Sunovion":[337],"SynAgile,":[339],"US":[341,370],"WorldMeds.":[342,371],"research":[347,400],"support":[348,401],"Bioelectron":[350],"Technology":[351],"Corporation,":[352],"Biotie":[353],"Therapies,":[354],"Michael":[358,404],"J.":[359,405],"Fox":[360,406],"Foundation":[361],"Research,":[364],"Parkinson":[365],"Study":[366],"Group,":[367],"Sunovion,":[368],"Claassen":[373,397],"Teva":[391],"Neuroscience,":[392],"Acadia,":[394],"AbbVie.":[395],"NIH/NINDS,":[403],"Foundation,":[407],"Huntington":[408],"Disease":[409],"Society":[410],"America,":[412],"Vaccinex,":[413],"AbbVie,":[414],"Auspex":[415],"Pharmaceuticals.":[416],"Olson":[418],"Neurocrine":[436,458,485,509,565],"Biosciences,":[437,459,486,510,566],"Inc.":[438,460,487,511,567],"Farahmand":[440],"supporter":[462,513],"this":[464,515],"Siegert":[467],"Alrais":[489],"Employee":[507],"Rocha":[518],"BIAL-Portela":[536],"&":[537],"Ca":[538],"SA.":[539],"Soares-da-Silva":[541],"nothing":[543],"disclose.":[545],"Liang":[547]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-05-09T00:00:00"}